Valuation of a drug to control obesity

A team of Cambridge MBAs beat 34 MBA teams from schools such as Harvard and Kellogg to place fourth in the annual Kellogg Biotech and Healthcare Case Competition. Listen to how the team arrived at a valuation for Contrave, an obesity drug currently undergoing clinical trials, and also how they learnt about the larger issues confronting the pharma industry. An interview with Conrad Chua, Head of MBA Marketing and Admissions